KKPCF (Kaken Pharmaceutical Co) Non Operating Income: $0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KKPCF Kaken Pharmaceutical Co Ltd KKPCF
61 GF Score
Price $26.00
GF Value $26.63
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Non Operating Income?

Kaken Pharmaceutical Co KKPCF 61 Non Operating Income is $0.0 Mil as of Mar. 2026. GuruFocus rates KKPCF with a GF Score™ of 61/100 and a GF Value™ of $26.63. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Kaken Pharmaceutical Co's Non Operating Income for the three months ended in Mar. 2026 was $0.0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Kaken Pharmaceutical Co Non Operating Income Related Terms

Kaken Pharmaceutical Co Non Operating Income Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Non Operating Income Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KKPCF
61GF Score
Kaken Pharmaceutical Co Ltd KKPCF
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.0 Mil mean?
Kaken Pharmaceutical Co (KKPCF) has a Non Operating Income of $0.0 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Non Operating Income too high?
Kaken Pharmaceutical Co's current Non Operating Income is $0.0 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Non Operating Income compare to ZTS?
Kaken Pharmaceutical Co's Non Operating Income of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Non Operating Income is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current Non Operating Income of $0.0 Mil. The stock's GF Value™ is $26.63, compared to a current price of $26.00 — trading 2.4% below its estimated fair value. The current Non Operating Income is $0.0 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current Non Operating Income is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be undervalued. The current stock price of $26.00 is trading 2.4% below its estimated GF Value™ of $26.63.

Key valuation signals for KKPCF:

  • Non Operating Income: $0.0 Mil
  • GF Value™: $26.63 vs. price of $26.00 (2.4% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kaken Pharmaceutical Co Business Description

Other Exchanges 4521:Japan
Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
61GF Score

Get the complete analysis for KKPCF

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.00
Price
$26.63
GF Value